NCT00002391已完成3 期
A Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of 1592U89/Zidovudine (ZDV)/Lamivudine (3TC) Versus the Combination of Zidovudine (ZDV)/Lamivudine (3TC) in HIV-1 Therapy-Experienced Pediatric Patients.
Glaxo Wellcome58 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 试验地点
- 58
研究概览
简要总结
To compare the safety, tolerance, durability of the viral load response and the antiviral activity of the 1592U89/zidovudine(ZDV)/lamivudine (3TC) regimen vs. ZDV/3TC regimen. To determine the clinical efficacy of the two regimens as measured survival, disease progression, weight growth velocity, and neuropsychological or neurological changes. To assess the development of viral resistance and relative pharmacokinetics associated with each regimen.
详细描述
Patients are randomized to receive blinded treatment with ZDV/3TC alone or in combination with 1592U89, orally for 16 weeks. If after the 16-week period certain criteria are met, patients may have the option to switch to open-label treatment for the remainder of the study period.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 3 Months 至 12 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Intravenous immunoglobulin G, erythropoietin, G-CSF and GM-CSF.
- •Opportunistic infection prophylaxis.
- •Patients must have:
- •HIV-1 infection documented by:
- •< 18 months of age:
- •one positive viral test culture and one other positive viral test (culture, PCR, p24 antigen, or Immune Complex Dissociation p24 antigen) on two different specimens.
- •>= 18 months of age:
- •two positive viral tests as stated above, one or both of which may be determined by a federally documented ELISA and confirmed by Western blot or Indirect Fluorescent Antibody test.
- •Any of the CDC Categories:
- •1, 2, 3, and N, A, B, and C of the 1994 Revised Classification System for HIV Infection in Children Less than 13 Years of Age.
- •CD4+ count >= 15% within 14 days prior to study drug administration.
- •No active or ongoing AIDS-defining opportunistic infection that precludes absorption of study drug or observation of a study parameter.
- •Signed, informed consent from parent or legal guardian for patients under 18 years of age.
排除标准
- •Co-existing Condition:
- •Patients with the following conditions or symptoms are excluded:
- •Serious bacterial infection that precludes absorption of study drug or observation of a study parameter.
- •Documented hypersensitivity to a nucleoside analog.
- •Co-enrollment in certain opportunistic infection protocols is not exclusionary if approval is obtained.
- •Malignancy.
- •Life-threatening infection or other chronic disease that may compromise patient safety.
- •Grade 3/4 clinical or laboratory toxicity or current grade 2 or higher pancreatic amylase or lipase toxicity as defined by the ACTG Toxicity Tables within 14 days prior to study entry.
- •Concurrent Medication:
- •Other anti-HIV therapy.
- •Probenecid.
- •Biologic response modifier (unless listed under included concurrent medication) and megestrol acetate.
- •Human growth hormone.
- •Immunomodulators and cytotoxic chemotherapeutic agents.
- •Systemic corticosteroids > 14 days without approval.
- •Investigational agents.
- •Concurrent Treatment:
- •Radiation therapy.
- •Patients with the following prior conditions are excluded:
- •History of clinically relevant pancreatitis or hepatitis within the past 6 months.
- •Participation in a vaccine trial.
- •Prior Medication:
- •Protease inhibitor therapy within 2 weeks prior to randomization.
- •Interleukins or interferons within 30 days prior to study drug administration.
- •Investigational drugs within 14 days prior to randomization.
- •HIV vaccine dose within past 30 days.
- •> 12 weeks prior antiretroviral therapy and unchanged therapy 12 weeks prior to screening.
研究者
研究点 (58)
Loading locations...
相似试验
已完成
3 期
A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.HIV InfectionsNCT00002199Glaxo Wellcome550
已完成
4 期
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis CLiver TransplantationHepatitis CNCT00938860Novartis Pharmaceuticals92
已完成
2 期
A Phase 2 Study Of PF-00232798 In HIV Positive PatientsHIVNCT00495677Pfizer43
Unknown
4 期
A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected PatientsHIVNCT00199121Johann Wolfgang Goethe University Hospital
已完成
3 期
Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 InfectionInfection, Human Immunodeficiency Virus IHIV InfectionNCT00440947ViiV Healthcare515